Kartoun, Uri
Khurshid, Shaan
Kwon, Bum Chul
Patel, Aniruddh P.
Batra, Puneet
Philippakis, Anthony
Khera, Amit V.
Ellinor, Patrick T.
Lubitz, Steven A.
Ng, Kenney
Article History
Received: 18 March 2022
Accepted: 12 July 2022
First Online: 22 July 2022
Competing interests
: Dr. Lubitz receives sponsored research support from Bristol-Myers Squibb/Pfizer, Bayer AG, Biotronik, and Boehringer Ingelheim, and has consulted for Bristol-Myers Squibb and Bayer AG. Dr. Ellinor receives sponsored research support from Bayer AG and IBM, and he has consulted for Bayer AG, Novartis, and MyoKardia, and Quest Diagnostic. Dr. Philippakis is also employed as a Venture Partner at GV and consulted for Novartis; and has received funding from Intel, Verily and MSFT. Dr. Batra serves as a consultant for Novartis. Dr. Khera has served as a scientific advisor to Sanofi, Amgen, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Novartis, Verve Therapeutics, Silence Therapeutics, Veritas International, Color Health, Third Rock Ventures, and Columbia University (NIH); received speaking fees from Illumina, MedGenome, Amgen, and the Novartis Institute for Biomedical Research; and received a sponsored research agreement from the Novartis Institute for Biomedical Research. Drs. Kartoun, Kwon, and Ng are employees of IBM. The remaining authors have no disclosures.